Posted by Michael Wonder on 21 Apr 2021
Novartis’ MS therapy Kesimpta wins NICE backing
21 April 2021 - Novartis’ Kesimpta has been recommended by NICE for the treatment of relapsing-remitting multiple sclerosis in adult patients.
Kesimpta (ofatumumab acetate) is the first self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS with active disease, according to Novartis.
